NYSE:HTGCCapital Markets
Hercules Capital Ties Savara Funding To FDA Milestone And Valuation Case
Hercules Capital (NYSE:HTGC) has amended its loan and security agreement with Savara Inc.
The amendment gives Savara access to additional non dilutive capital if the FDA approves its lead therapy.
The structure ties Hercules Capital's future funding to a key regulatory outcome for Savara.
For Hercules Capital, a venture lending specialist with a focus that includes life sciences, this updated agreement deepens its role in biotech financing. Shares recently closed at $18.70, and the stock...